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Abstract. Reticulocyte-binding homologues (RH) are a ligand family thatmediatesmerozoite invasion of erythrocytes
inPlasmodium falciparum. Among the fivemembers of this family identified so far, onlyP. falciparum reticulocyte–binding
homologue-5 (PfRH5) hasbeen found tobe essential for parasite survival across strains that differ in virulenceand route of
host-cell invasion. Based on its essential role in invasion and early evidence of sequence conservation, PfRH5 has been
prioritized for development asavaccinecandidate.However, little is knownabout theextent of genetic variability ofRH5 in
the field and the potential impact of such diversity on clinical outcomes or on vaccine evasion. Samples collected during a
prospective cohort study of malaria incidence conducted in Kalifabougou, in southwestern Mali, were used to estimate
genetic diversity,measure haplotype prevalence, and assess thewithin-host dynamics of PfRH5 variants over time and in
relation to clinical malaria. A total of 10 nonsynonymous polymorphic sites were identified in the Pfrh5 gene, resulting in
13 haplotypes encoding unique protein variants. Four of these variants have not been previously observed. Plasmodium
falciparum reticulocyte–binding homologue-5 had low amino acid haplotype (h = 0.58) and nucleotide (π = 0.00061)
diversity. By contrast to other leading blood-stage malaria vaccine candidate antigens, amino acid differences were not
associated with changes in the risk of febrile malaria in consecutive infections. Conserved B- and T-cell epitopes were
identified. These results support the prioritization of PfRH5 for possible inclusion in a broadly cross-protective vaccine.
INTRODUCTION
The efficacy of vaccines targeting Plasmodium falciparum,
the deadliest human malaria parasite, has been limited in part
by genetic diversity in the vaccine antigens in endemic
areas,1,2 resulting in higher protection against parasites car-
rying alleles identical to the vaccine genotype.3–6 Molecular
epidemiological surveys of P. falciparum genetic diversity at
vaccine-testing sites can identify the most prevalent genetic
variants of candidate antigens for consideration in designing
broadly protective vaccines and assess the role of specific
polymorphisms in strain-specific immunity.4
Plasmodium falciparum reticulocyte–binding protein
homologue-5 (PfRH5) is a promising newblood-stage vaccine
antigen that ismoving quickly toward clinical development.7–9
The invasion of merozoites into the erythrocyte is a multistep
process that starts with merozoite binding and reorientation
onto the red blood cell (RBC), followed by the formation of a
tight junction and culminates with parasite entry into the
erythrocyte. Essential to this process is PfRH5, a 63-kDa
protein encoded by a gene located in the subtelomeric region
of chromosome 4. The gene (PF3D7_0424100) is 1,581 nu-
cleotides long and is refractory to knockout in diverse
strains.10 The erythrocyte receptor for RH5 is basigin (CD147),
and antibodies specific to either RH5 or basigin inhibit eryth-
rocytic invasion byP. falciparum in a dose-dependentmanner
in in vitro tests.11 Furthermore, IgG antibodies induced after
PfRH5 immunization have higher potency for controlling RBC
invasion by both homologous and heterologous P. falciparum
strains in growth inhibition assays, as compared with IgG
raised against the apical membrane antigen-1 (AMA1) and
merozoite protein-1, two other leading blood-stage vaccine
antigens.12
Importantly, the pfrh5 gene exhibits limited polymorphism
across multiple P. falciparum laboratory strains10,13 and
geographic isolates.14 Moreover, allelic exchange experi-
ments have determined that specific PfRh5 residues are
critical for host erythrocyte invasion. For example, a non-
synonymous change in codon 204 (I204K) converted a poorly
invasive strain into a highly invasive one.10 In a separate set of
experiments, this invasion-enabling single nucleotide poly-
morphism (SNP) at position 204 changed the protein structure
and greatly modified its binding specificity and infectivity.15
Taken together, these findings suggest that the functional
requirement for erythrocyte invasion exert strong purifying
selection on the locus and might constrain the genetic di-
versity of pfrh5. To evaluate the potential clinical implications
of this hypothesis and to generate more evidence on the ex-
tent of natural diversity in PfRH5 at a single vaccine-testing
field site, we investigated the prevalence and dynamics of
pfrh5 polymorphisms during acute malaria episodes inMalian
children and adults. Longitudinal analyses were carried out to
assess whether specific pfrh5 alleles, or changes at this locus
in consecutive infections, are associated with the develop-
ment of malaria symptoms. This prospective study aimed to
identify specific PfRH5 amino acid residues that are critical in
clinical malaria, and to identify conserved B- and T-cell epi-
topes that should be taken into account in the design of a
malaria vaccine intended to provide broader, strain-
transcending protection against diverse parasites than was
achieved with first-generation blood-stage malaria vaccines.
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MATERIALS AND METHODS
Sample origin. Samples used in this study originated from
Kalifabougou, a rural village located 45 km northwest of
Bamako, Mali. Malaria transmission is seasonal (June–
December) and hyperendemic, with seasonal peaks following
the rains in July through October. The study population and
clinical parameters have been described previously.16 Briefly,
695 healthy children and adults, aged 3 months to 25 years,
were enrolled in this ongoing study beginning in May 2011.
Samples and clinical data for this study were collected from
May 2011 through January 2012. Study participants were
surveyed during scheduled visits occurring every 2weeks and
anytime they presented with malaria-like symptoms. During
surveillance, clinical parameters were measured and malaria
parasites were detected by thick smears. For this study, a
clinical malaria episode was defined as any parasitemia by
blood smear with a temperature greater or equal to 37.5C.
Participants with positive blood smears were treated accord-
ing to the National Malaria Control Program guidelines in Mali.
Peripheral whole-blood samples were collected by finger stick
in capillary collection tubes (Sarstedt, Newton, NC) for the
cryopreservation of the cell pellet and/or as dried blood spots
(DBS) on 903 filter paper (Whatman/GE Healthcare, Piscat-
away, NJ). Longitudinal polymerase chain reaction (PCR)
analysis of DBS collected at scheduled visits was performed
as previously described.17 Whole-blood samples from partic-
ipants with at least two malaria episodes during the season
were selected for genomic DNA (gDNA) extraction as de-
scribed below (Figure 1).
DNA extraction and genotyping.Whole-blood gDNA was
extracted from blood samples and DBSs using the QIAmp 96
DNA kit (Qiagen, Valencia, CA). To genotype polymorphisms
in pfrh5, a nested-PCR was used to amplify the major exon
in all the samples. Briefly, primers F1 (59 GCAATAAAAAA
AACGAAGAATCAAGA 39) and R1 (59 TGAAAATATTCCA
TTTTAATTGGGAC 39) were used in the primary PCR reaction
(1,465 bp). Conditions for this amplification were 94C for 5
minutes, followed by 35 cycles of denaturation at 94C for 1
minute; primer annealing at 48C for 1 minute, and extension
at 60C for 1.5 minutes with a final extension at 60C for
5 minutes. PCR products from the first amplification were
subsequently used as a template for a second round of
amplification (1,418 bp) with primers F2 (59 GAAAATAATCT
GACGTTACTACCA 39) and R2 (59GACATCATTGAACTTCAT
TTGTAG 39). Amplification conditions were the same as in the
primary amplification with only 10 cycles instead of 35. PCR
reactionswere carried out in a total volume of 50 μLwith 47 μL
of Platinum Super Mix in 96-well plates (Invitrogen, Carlsbad,
CA), 1 μL of each primer (1 μM final concentration) and 1 μL of
malaria parasite DNA. Secondary PCR had 47 μL of Platinum
Mix, 1 μL of each (1 μM final concentration) primer and 1 μL of
primary PCR product. Secondary PCR products were elec-
trophoresed on a high-throughput precast gel system (Invi-
trogen), then visualized and photographed under ultraviolet
light with ethidium bromide as the stain.
PCR products were purified using filter plates (Edge Bio-
systems, Inc., Gaithersburg, MD) attached to a vacuum mani-
fold and eluted in water, and sequenced in a 10 μL reaction
using BigDye v3.1 (Applied Biosystems, Carlsbad, CA). The
sequencing products were ethanol precipitated and run in 7 μL
HiDi formamide on an ABI 3730XL 96-capillary sequencer
(Thermo Fisher Scientific,Waltham,MA). Following sequencing,
fragments were assembled, edited and aligned to P. falciparum
3D7 reference (GenBank accession number: XM_001351508)
sequence using Sequencher v.5.0 (Gene Codes Corporation,
Ann Arbor, MI). Infections were classified as single/predominant
allele infections or as multiple allele infections if the secondary
peak height was greater than 50%of the primary peak height at
any polymorphic position. Sequence alignment was performed
using Bioedit version 7.18
Population genetics analysis.Haplotypeswere definedas
an uninterrupted sequence of nucleotides or amino acid se-
quence variants, and the pfrh5 locus of the P. falciparum 3D7
strain (GenBank accession number: XM_001351508) was
used as the reference sequence for all the comparisons. The
nucleotide diversity at the locus, among sequences generated
from samples collected during the study, was assessed by
estimating the parameterπ, the average number of nucleotide
differences per site between two random sequences.19
Bootstrap resampling was used to simulate the distribution of
π and to calculate confidence intervals (CIs). These analyses
were conducted using MEGA620 and DnaSP v5.21 The prev-
alence of nonsynonymous substitutions was estimated using
SAS v9.1 (SAS Institute Inc., Cary, NC). To assess if regions of
Pfrh5 evolve under neutrality (Kimura 1983), the McDonald
and Kreitman test was measured using Plasmodium reich-
enowi (PRCDC_0322700) as an outgroup, and analyses were
performed using DnaSP v5.21 The hypothesis that positive
selection has occurred in PfRH5 branch/branches tree was
FIGURE 1. Within-host dynamics of Plasmodium falciparum reticulocyte–binding homologue-5 (PfRH5) amino acid polymorphisms during
consecutive malaria infections. The gray color represents asymptomatic infections, and the white color represents clinical malaria. Different
abbreviations (Asparagine:N, Lysine:K,Glycine:G, andGlutamate: E) indicate different alleles at a polymorphic amino acid sitewithinPfRH5. In this
hypothetical example, at this amino acid position, the individual goes from being asymptomatic during his first two infections (N then K) to
symptomatic during his third infection (G). The individual is later infected with variants harboring different amino acids than the previous two
infections but in one instance similar to the first infection (N).
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assessed by applying the branch-site test22 and the branch-
site unrestricted statistical test for episodic diversification
(BUSTED) implemented in the HYPHY package.23 Although
BUSTED identifies the effect of sporadic positive selection on
a subset of branches in the lineage, the branch-site test uses a
χ2 distributionwith onedegree of feedom to compare amodel,
which allows positive selection on one or more variants of a
group to a model that does not permit positive selection (P <
0.05 for sites positively selected). Tajima’sD statistic was also
calculated, with a positive value of Tajima’s D indicating an
excess of alleles at intermediate frequency, consistent with
balancing selection, and negative values consistent with di-
rectional selection or with rapid population expansion fol-
lowing a bottleneck. To assess recombination events in pfrh5,
which may result in negative Tajima’s D values and lead to a
false inference of directional selection or rapid expansion, an
estimate of recombination (R) and the minimum number of
recombination events (RM)24 in the data were estimated using
DnaSPv5. These recombination eventswere confirmedby the
genetic algorithm recombination detection test.25 Genetic
association between polymorphic sites and the effect of in-
tragenic recombination on sequence polymorphism were
assessed using the Zns
26 and the ZZ27 statistics, respectively.
To group PfRH5 sequences, a sequence clustering analysis
was conducted. Structurama, a Bayesian clustering algorithm
software,28 which treats the number of populations as a ran-
dom variable, was used to determine the posterior number of
populations (K).We identified two populations by this Dirichlet
process.We then usedStructure version 2.3.329 to assignRh5
sequences to haplotype groups. Ten runs of 50,000 burn-ins
and 100,000 iterations were performed for K = 2 using an
admixture model.
Within-host amino acid dynamics. The frequency of pro-
tein sequence variants, or haplotypes (N = 13), and of amino
acid residue polymorphic sites (N = 10) were compared in
clinical and asymptomatic malaria cases using a χ2 test while
correcting formultiplemeasurements (twosideP values: 0.05/
13 = 0.003 and 0.05/10 = 0.005, respectively). Generalized
estimating equations were used to perform logistic regression
to estimate whether specific pfrh5 alleles or shifts in pfrh5
alleles were associated with the development of clinical
symptoms in an individual’s consecutive infections. Both
single- and multiple-clone infections were included in the
analysis. The primary outcome was whether an individual’s
second of two paired consecutive infections was symptom-
atic or asymptomatic, with the presence of infection being
defined basedon the results of thepfrh5PCR (Figure 1). Study
participants’ paired consecutive episodes were classified as
follows: absence of infection to asymptomatic (OA, N = 40);
absence of infection to symptomatic (OS, N = 9); asymptom-
atic to asymptomatic (AA, N = 58); asymptomatic to symp-
tomatic (AS, N = 16); symptomatic to asymptomatic (SA, N =
13); and symptomatic to symptomatic (SS,N = 3). The primary
predictor for the analysis was the presence of a specific pfrh5
variants or whether there was a change in amino acid se-
quence variant in the next consecutive infection. The models
included potential confounding variables such as age group,
or symptoms in the first of the two infections. Analysis was
performed using SAS v9.1.
B- and T-cell epitopes. Plasmodium falciparum reticulocyte–
binding homologue-5 linear B-cell epitopes were predicted
using the ABCpred server (http://www.imtech.res.in/raghava/
abcpred) using a threshold of 0.85. A T-cell epitope prediction
algorithm (NetMHCpan-3.0, http://www.cbs.dtu.dk/services/
NetMHCIIpan-3.0) was used to screen PfRH5 sequences
for potential CD4+/CD8+ epitopes with respect to the most fre-
quent human leukocyte antigen (HLA) allele frequencies in
Mali.30,31 Disordered regions (intrinsically unstructured regions
[IURs]; over-representation of few residues with low predicted
secondary structure) were identified using the regional order
neural network (RONN) server (http://www.strubi.ox.ac.uk/
RONN). A putative epitope cutoff was set at 50 nM (high affinity
binding).
Human subject protections. The study protocols were
reviewed and approved by the institutional review boards of the
UniversityofSciences,Techniques, andTechnologyofBamako,
Mali; the University of Maryland Baltimore; and the National In-
stitute of Allergy and InfectiousDiseases. The study participants
gave their consent and/or assent to participate in the study.
RESULTS
Data summary. Blood spots on filter paper and/or whole-
blood specimens (N = 312) were selected from the incidence
study sample repository. Samples had been collected bi-
weekly from individuals with at least two malaria episodes
during study follow-up starting at the beginning of the 2011
malaria transmission season. Of these specimens, 198
(63.5%) were successfully sequenced using primers specific
to the Pfrh5 gene. The dynamics of consecutive malaria in-
fections and clinical episodes was assessd using 139 se-
quences generated from paired-consecutives episodes as
described in Table 1. Amino acid sequence variants were
defined based on single amino acid polymorphisms. Of the
198 sequences generated (GenBank accession number:
MG012489–MG012686) and based on the quality of the se-
quences, all individuals had only one haplotype.
Polymorphismsandhaplotypeprevalenceofpfrh5gene.
Ten nonsynonymous polymorphisms were identified in pfrh5.
These mutations and the amino acid residues in which they
TABLE 1
Dynamics of malaria infections and clinical episodes in male and
female consecutive infections according to age groups.
Characteristic Male Female Male/Female ratio
OA
£ 5 years 17 16 1.06
> 5 years 2 5 0.40
OS
£ 5 years 4 2 2
> 5 years 2 1 2
AA
£ 5 years 24 25 0.96
> 5 years 4 5 0.80
AS
£ 5 years 6 8 0.75
> 5 years 1 1 1
SA
£ 5 years 6 3 2
> 5 years 3 1 3
SS
£ 5 years 2 1 2
> 5 years 0 0 0
Total 71 68 1.04
Study participants’ paired consecutive episodes were classified as follows: absence of
infection to asymptomatic (OA); absence of infection to symptomatic (OS); asymptomatic to
asymptomatic (AA); asymptomatic to symptomatic (AS); symptomatic to asymptomatic (SA);
symptomatic to symptomatic (SS).
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are present are described as follows: D67E, N117S, Y147H,
H148D, C203Y, D249Y, D305G, V371I, I407V, and I410M. The
most common polymorphisms were C203Y (66.8%) followed
by H148D (5%). Based on these 10 amino acids polymor-
phisms, 13 unique protein variants were identified (Table 2).
Seven of these variants were seen only once in the current
dataset. The most frequent variant, which we define by the
composition at the 10 variable residue positions (variant A:
DNYHYDDVII), had a prevalence of 57.3% whereas the fre-
quency of the second most prevalent variant (Variant B:
DNYHCDDVII) was 30.7% (Table 2). An analysis by the
Dirichlet process using Structurama identified these two
groups as the main populations in this transmission site. An
analysis of the distribution and dynamics of variants during the
8 months of follow-up showed that the incidence of variants A
and B were only different in July (P = 0.03, χ2 = 4.5). In-
terestingly, the incidenceof the twomajor haplotypesfluctuate
slightly and alternate over time (Figure 2), which is character-
istic of frequency-dependent selection. Also, no difference
was seen in the incidence of the C203Y and the H148D mu-
tations during follow-up (χ2 = 8.01, P = 0.33; and χ2 = 3.18, P =
0.86, respectively).
Genetic diversity parameters were estimated for the whole
pfrh5 gene. At this study site, pfrh5 nucleotide diversity (π ±
SD) and haplotype diversity (h ± SD) were 0.00061 ± 0.00005
and 0.58 ± 0.027, respectively. All polymorphisms in the data
occurred at nonsynonymous sites, with πS = 0 and πN =
0.00075. The average number of pairwise nucleotide differ-
ences between sequences in this sample set was 0.74.
To assess whether positive selection might be responsible
for the low diversity observed in pfrh5 and influence its
eventual use as a vaccine candidate, the McDonald and
Kreitman test was conducted with P. reichenowi used as a
source of the divergence estimates to be compared with
polymorphism in P. falciparum. Despite the higher rate of
nonsynonymous polymorphism relative to synonymous
polymorphism, the test does not support a departure from
neutral expectation (two-tailedP value = 0.55). Thismay result
from the lack of power due to the small number of polymorphic
sites, which was exacerbated by the elimination from the test
of three codonswithmultiple variable positions.Moreover, the
estimate of the coefficient of variation for αs generated using a
maximum likelihood model (gamma distribution with shape 1)
was small (< 0.000001) inferring a constant evolution rate
among sites. Finally, the Tajima’sD statistic did not showclear
departure from neutrality (Tajima’s D = −1.32; as a rule of
thumb, a D statistic with absolute value less than 2 is not
considered significant). Despite not being significant, the
strong negative Tajima’sD valuemay be suggestive of a rapid
population expansion following a bottleneck.
Recombination is a process that creates newhaplotypes by
reassorting variants of a locus. These novel haplotypes may
be different from the vaccine allele(s), limiting its efficacy. To
evaluate this second source of genetic diversity in the dataset,
the contribution of recombination to pfrh5 diversity was esti-
mated. Sequence analyses suggested that the overall re-
combination parameter (R), which is the recombination rate
per generation between the most distant sites of Pfrh5, was
77.3. An estimate of R between adjacent sites of Pfrh5 was
0.064, whereas theminimumnumber of recombination events
(Rm) in the history of the dataset was one. These findings are
TABLE 2
Reticulocyte-binding like homologous protein 5 (PfRH5) variant frequency and single nucleotide polymorphisms in Mali isolates
D67E N117S Y147H H148D C203Y D249Y D305G V371I I407V I410M
Protein variant Variant – – – – – – – – – – Frequency (%)
DNYHYDDVII A D N Y H C D D V I I 57.3
DNYHCDDVII B – – – – Y – – – – – 30.7
DNYHYDDVVI C – – – – Y – – – V – 3
DNYDYDDVII D – – – D Y – – – – – 2.5
DNHDYDDVII E – – H D Y – – – – – 2
DNYHCDDVVI Other – – – – – – – – V – 1
DNYDYDDVVI Other – – – D Y – – – V – 0.5
DNYHCDDVIM Other – – – – – – – – – M 0.5
DNYHCYDVII Other – – – – – Y – – – – 0.5
DNYHYDDIII Other – – – – Y – – I – – 0.5
DNYHYDGVII Other – – – – Y – G – – – 0.5
DSYHCDDVII Other – S – – – – – – – – 0.5
ENYHYDDIII Other E – – – Y – – I – – 0.5
Prevalence of the major
amino acid
– 99.5 99.5 98 95 67 99.5 99.5 99 95.5 99.5 –
PfRH5 = Plasmodium falciparum reticulocyte–binding homologue-5.
Polymorphic codons ofPfrh5 gene comparedwith the 3D7 strain (XM_001351508). Haplotype prevalences are reported in the right panel. Themost prevalent amino acid frequency is listed in the
bottom panel.
FIGURE 2. Dynamics of Plasmodium falciparum reticulocyte–
binding like homologous protein 5 haplotype during 8 months of
follow-up. Incidence of the two major RH5 haplotypes from May to
December in Kalifabougou, Mali. “n” represents the sample size per
time point, and bracket are error bars.
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indicative of meiotic recombination occurring within the Pfrh5
locus. Values of the genetic association estimated between
polymorphic sites (Zns) and the effect of intragenic re-
combination (ZZ) on sequence polymorphism were 0.0216
and 0.0256, respectively, indicative of low linkage disequilib-
rium between polymorphic sites.
Dynamicsofaminoacids in relation tomalariasymptoms.
Participants who had clinical malaria experienced one to five
malaria episodes during the 9-month study period. Nearly half
(48%)of theseparticipantsexperienced threemalariaepisodes.
A logistic regression model was used to estimate whether
specific pfrh5 alleles were associated with the development of
clinical symptoms in consecutive infections. The primary pre-
dictor for theanalysiswas thepresenceof a specificpfrh5allele.
Only amino acid 203 had enough changes during follow-up to
assess the dynamics of codons in relation to the occurrence of
malaria clinical episode. Results from the regressionmodels for
amino acid 203 (95% CI: −1 to 1.1) analysis did not show
an association between amino acid residue at position 203
and the occurrence of clinical malaria episode in consecutive
P. falciparum infections. Finally, a comparison ofmean parasite
density in mutated (203Y: 20852; 95% CI: 14,390–27,313) and
wild type (203C: 33745; 95% CI: 19,340–48,150) parasites at
position 203 revealed that neither of the amino acids at this site
was associated with the level of parasitemia.
Pfrh5 variants and malaria clinical episodes. To in-
vestigate whether individual codons or PfRH5 variants affected
the risk of clinical malaria episodes, association between the
mostprevalentPfRH5variants and residuesand the incidenceof
clinical malaria was evaluated. Neither variant A (χ2 = 2.46, P =
0.12) nor variant B (χ2 = 2.45, P = 0.11) was associated with
malaria risk. Furthermore, the incidences of two of the most
prevalent amino acid polymorphisms, H148D and C203Y, were
identical ([χ2 = 0.001, P = 0.97] and [χ2 = 5.30, P = 0.02], re-
spectively) in studyparticipantswhenmalaria clinical caseswere
compared with asymptomatic infections (P value corrected for
multiple comparisons, P = 0.05/10 = 0.005).
Antigenic diversity of B-cell and T-cell epitopes
within PfRH5. To ascertain whether a subset of epitopesmay
replace the whole PfRH5 antigen as a conserved immunogen,
IURs in addition to B- and T-cell epitopes were identified and
screened for the presence of polymorphisms. Three B-cell
epitopes, eight major histocompatibility complex (MHC) class
I-restricted T-cell epitopes, 175 MHC class II-restricted T-cell
epitopes, and three IURs (highly disordered) were identified
(Figure 3, Table 3). Eight of 10mutations in thepfrh5genewere
located in antigenic/epitope regions (χ2 = 8.1, P = 0.004)
(Figure 3), revealing a significant polymorphisms enrichment
in regions of immunogenic potential. A conserved region
(amino acid residues 250–304) located in the middle of the
gene was highly disordered (over-representation of few resi-
dues with low predicted secondary structure) but also enriched
in B-cell epitopes.
DISCUSSION
Plasmodium falciparum reticulocyte–binding homologue-5
is a conserved malaria vaccine candidate that induces anti-
bodies that are protective in in vitro assays,32 non-human
primate studies7 and field studies.16,33 Plasmodium falcipa-
rum reticulocyte–binding homologue-5 interacts with basigin
(CD147), an erythrocyte surface protein, to allow the invasion
of the malaria parasite into the erythrocyte. The goal of this
studywas to assess the genetic diversity, haplotype prevalence,
and dynamics of the PfRH5-encoding gene to guide the selec-
tion of variants and/or B- and T-cell epitopes that are represen-
tative of the parasite population of this study site for possible
inclusion in a broadly effective malaria vaccine. Examining the
dynamics of antigen diversity in prospective cohort studies can
show evidence to guide the design of vaccines that will be effi-
cacious against diverse targets. Clinical trials have shown that
some malaria vaccines based on a single strain induce pro-
tection that is specific to the vaccine strain.5,34–36 Likewise,
pneumococcal37 and influenza38 vaccine trials have shown the
importance of antigen polymorphisms on vaccine efficacy and
the selection of variants to include in vaccine formulations.
In the present study, we analyzed 198 sequences from
Kalifabougou, Mali. Power calculations based on sequences
FIGURE 3. Plasmodium falciparum reticulocyte–binding homologue-5 peptide locations within the gene. Polymorphic residues are in lower case
font. B-cell epitopes are underlined in plain black whereas HLA Class II (antigen D related beta chain [DRB]1, and DQB1) epitopes are underlined,
respectively with ( ) and ( ) dashed lines. Dashed ( ) and ( ) lines are shown under HLA Class II DRB4 and DRB5 epitopes, respectively.
MHC class I epitopes are bolded. Number in parenthesis represent the total number of epitopes identified in this dataset. Legends. IUR = intrinsically
unstructured regions; SNPs = single nucleotide polymorphism.
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extracted from MalariaGEN database show that, with this
sample size, we have 83.6% power to identify 85.7% of all
alleles present, suggesting that this sample size provides a
reliable assessment of population diversity. Two protein var-
iants that representmost of the circulating alleles in this region
were identified. In support of previous findings based on small
numbers of parasite strains,10,11,39 our large field study con-
firmed that pfrh5 was highly conserved in a setting where
other vaccine antigens show extensive polymorphism. The
nucleotidediversity, asmeasuredbyπ,wasvery low (0.00061±
0.000012) compared with the diversity observed in the locus
encoding the well-known blood-stage AMA1 (0.0163) from
the same geographical region.40 Despite the high rate of poly-
morphism in nonsynonymous relative to synonymous sites,
usually suggestive of positive selection, none of the statistical
inferencemethodsused todetectdeparture fromneutralitywas
indicative of evolution under immune pressure, possibly be-
cause the tests were underpowered to detect it in this dataset.
In addition, recombination events that may introduce new
protein sequence variants in the locus were very low (only one
event observed), as indicated by low R, Rm, Zns, and ZZ sta-
tistics. The low effective recombination rate may also be
explained by the limited number of variable sites that are not
singletons, which prevents the detection of recombination
events. The very low values of nucleotide diversity not only in
nonsynonymous (πNS) sites but also in silent sites (πS) and
observed in this dataset are usually indicative of a very recent
commonancestor to all sequences, asonemight expect froma
hard sweep or a recent, strong bottleneck. This observation is
consistent with a previous study that suggests that a small
chromosomal region containing Pfrh5 and three other genes
was recently acquired via lateral gene transfer from another
Plasmodium lineage, possibly an ancestor of Plasmodium
adleri,41 anevent thatwould impactpolymorphismsimilarly toa
very recent bottleneck.
Ten nonsynonymous SNPs were identified in pfrh5, which
gave rise to 13 protein variants with frequencies ranging from
0.5% to 57%. In comparison, using sequences from the
blood-stage vaccine candidate AMA1, 186 unique amino acid
haplotypes were identified in Bancoumana (prevalences
ranging from 0.3% to 2.54%)40 and 214 unique haplotypes
were observed in Bandiagara (prevalences from 0.2% to
3.6%),5 two other towns in Mali. Plasmodium falciparum
reticulocyte–binding homologue-5 amino acid polymorphism
C203Y, located near the boundary of the region involved in the
PfRH5–basigin interaction was the most variable residue ob-
served in this dataset. None of the codons within PfRH5-
basigin interface (S197, I204, N347, Y358, and E362)42 were
polymorphic. The conservation of these residues is sugges-
tive of the functionally critical role they play in the interaction
between PfRH5 and basigin to allow parasite invasion into
RBCs. The overall conservation of pfrh5 is highly unusual for
whatwould be expected of a genewith high expression during
the blood-stage and for which the product is exposed to the
host’s immune system, and therefore more inclined to exhibit
a high degree of amino acid diversity.43,44 However, as men-
tioned previously, these observations may be more reflective
of the unusual evolutionary history of the pfrh5 locus in
P. falciparum41 than of its interactionswith the human immune
system.
It is also possible that the protein has limited exposure
to the immune system as it has to form a complex with
P. falciparum reticulocyte–binding protein homologue-5-
interacting protein45 and P113.46 Therefore, polymor-
phisms in this protein may be found at flexible or exposed
sites.Findings fromKenya47andMali,16 suggest thatanti-PfRH5
antibody concentrations were very low in malaria-exposed
subjects compared with other blood-stage antigens, pro-
viding support for the notion that PfRH5 is either non-
immunogenic or that its immunogenicity is undermined
by mechanisms that reduce immune recognition or re-
sponse. The low antigenicity of PfRH5 in natural settings
will likely require the use of a potent adjuvant in a RH5-
based vaccine to induce the high antibody levels needed
for protection.
Using naturally-occurring clinical malaria episodes, we
assessed whether specific pfrh5 alleles were associated
with clinical disease, suggesting that certain alleles may
allow for more efficient erythrocyte invasion and potentially
more virulent infections. This study did not identify amino
TABLE 3
Potential high binding (IC50 < 50 nM) CD8+ T-cell, CD4+ T-cell, and
B-cell epitopes in Plasmodium falciparum reticulocyte–binding
homologue-5
Allele Predicted peptide
IC50
(nM)
MHC
restriction
Number of
polymorphic
sites
T-cell epitopes
Class I
HLA-A*23:01 KYLFIPSHNSFI 9.08 0
HLA-A*30:01 KIKLNIWRTFQK 16.15 0
HLA-B*35:01 YTFLDYYKHLSY 19.23 0
HLA-B*35:01 FVIIPHYTFLDY 22.85 0
HLA-A*30:01 GIRYHYDEYIHK 24.39 0
HLA-A*02:01 ILQEKEGHLDFV 27.43 0
HLA-A*23:01 TYGKCIAVDAFI 38.75 1
HLA-A*30:01 KTNNAKDHSTYI 44.27 0
Class II
DRB1_1304 KLILSVKSKNLN 33.82 1
SYIYIDTIKFIH 35.44 2
HKLILSVKSKNL 36.13 1
TNILQQSELLLT 40.87 0
GSYIYIDTIKFI 43.09 2
IKFIHKEMKHIF 43.28 1
SELLLTNLNKKM 44.77 0
TKIINDKTKIIQ 45.48 0
DRB1_0701 KYLFIPSHNSFI 32.95 0
YLFIPSHNSFIK 39.41 0
KLILSVKSKNLN 40.14 1
HKLILSVKSKNL 44.98 1
SNYNIANSIDIL 49.01 0
DRB1_1101 YIHKLILSVKSK 29.07 1
HKLILSVKSKNL 30.62 1
KLILSVKSKNLN 33.20 1
LKYLFIPSHNSF 35.97 0
EYIHKLILSVKS 34.24 1
KYLFIPSHNSFI 41.07 0
IHKLILSVKSKN 41.24 1
IKFIHKEMKHIF 44.58 1
DRB1_0120 KYLFIPSHNSFI 8.430 0
KLILSVKSKNLN 8.80 1
LKYLFIPSHNSF 9.77 0
HKLILSVKSKNL 11.39 0
LILSVKSKNLNK 11.66 1
GLKYLFIPSHNS 12.49 0
YLFIPSHNSFIK 12.23 0
B-cell epitopes
KKYSVFNQINDG 1
DSYRYDISEEID 0
EIDNDKENIKTN 1
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acids that were associated with the parasite’s ability to in-
vade RBCs, at least as measured by association with clin-
ical outcomes. All residues at position 204 in this dataset
were shown to be wild type, suggesting a high relative fit-
ness of an isoleucine (I) in this position. Although this post
hoc analysis was based on a relatively small number of paired
consecutive infections, the very low degree of polymorphism in
PfRH5comparedwithother blood-stageantigens supports the
conclusion that not enough time has occurred for genetic var-
iants to emerge.
Identifying epitopes that are conserved and localized in in-
trinsically unstructured regions of PfRH5 has important im-
plications for vaccine design. Our study revealed 21 B- and
T-cell epitopes that are conserved and located in disordered
regions across all the sequences from the Kalifabougou site.
Based on our data, the inhibition activity of these epitopes
and/or fragments should be assessed by functional assays to
ascertain their relevance as candidate epitopes of a PfRH5-
based vaccine.
We have advocated routinely assessing whether poly-
morphism in vaccine candidates is immunologically important
and therefore relevant to vaccine development. The data re-
ported here on the diversity and dynamics of this antigen’s
alleles and their association with the hazard of clinical malaria
episodesmay inform the design of a PfRH5-based vaccine or,
more likely, of a multivalent, multistage malaria vaccine that
improves on the modest efficacy of the first-generation vac-
cines.48 The results of this study suggest that polymorphism in
PfRH5 is very limited, stable during consecutive infection that
occur over the course of a malaria transmission season and
not associated with clinical risk. This high degree of conser-
vation and lack of association between genetic variation and
clinical disease is in sharp contrast to other leading blood-
stage vaccine antigens whose efficacy was constrained by
allelic escape.3,5,34,49,50 Although encouraging for PfRH5’s
prospects as a vaccine, even this limited degree of poly-
morphismallows for the possibility of vaccine escape and allele-
specific efficacy under the intense selection of vaccination as
supported by the apparent signal of frequency-dependent se-
lection. Moreover, although changes in the P. falciparum cir-
cumsporozoite protein (CSP) were not associated with clinical
risk in paired consecutive infections,51 the CSP-based vaccine
RTS,S nevertheless did have allele-specific efficacy.6 If the
predominant alleles identified in this study are confirmed to
predominate in other epidemiological settings, it would be pru-
dent to include both alleles in a vaccine containing PfRH5 to
reduce the effect of allele-specific efficacy.
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